Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,373 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,067 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (618)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06294548 | A Study of Valemetostat Tosylate (DS-3201b) With Atezolizumab and Bevacizumab in HCC | recruiting | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT06582017 | Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | recruiting | Phase 1 | 100 | Nammi Therapeutics IncINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07227168 |
| A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer |
| recruiting |
| Phase 1 |
| 200 |
| Sutro Biopharma, Inc.INDUSTRY |
| 1 |
| Aug 27, 2026 |
| clinicaltrials |
| NCT07544589 | A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers | recruiting | Phase 1 | 66 | Dispatch BiotherapeuticsINDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07630961 | Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors | recruiting | Phase 1 | 66 | Novartis PharmaceuticalsINDUSTRY | 2 | Aug 27, 2026 | clinicaltrials |
| NCT07640295 | Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations | recruiting | Phase 1 / Phase 2 | 80 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07658196 | TLR9 Immunotherapy for Peritoneal Carcinomatosis(TIPC) | recruiting | Phase 1 | 24 | Brown UniversityOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04157127 | Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma(DECIST) | recruiting | Phase 1 | 18 | Diakonos Oncology CorporationINDUSTRY | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT06586515 | MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors(MOONRAY-01) | recruiting | Phase 1 | 630 | Eli Lilly and CompanyINDUSTRY | 9 | Aug 24, 2026 | clinicaltrials |
| NCT07623369 | A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 299 | Huahui HealthINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05269381 | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors(PNeoVCA) | recruiting | Phase 1 / Phase 2 | 138 | Mayo ClinicOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06225011 | Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer | recruiting | Phase 1 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07619313 | AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer | recruiting | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07214298 | Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 35 | Roswell Park Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT07182149 | A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors | recruiting | Phase 1 | 150 | Normunity AccelCo, Inc.INDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04895709 | A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 1,109 | Bristol-Myers SquibbINDUSTRY | 8 | Aug 17, 2026 | clinicaltrials |
| NCT07157033 | A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.(XER-001) | recruiting | Phase 1 / Phase 2 | 36 | Xerient PharmaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05985655 | Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors(ELUCIDATE) | recruiting | Phase 1 / Phase 2 | 230 | Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 13, 2026 | clinicaltrials |
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT05706129 | A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 270 | Lumara Bio Oncologics GmbHINDUSTRY | 2 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT07733674 | Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)(RMX-VH) | recruiting | Phase 1 | 20 | Radiomedix, Inc.INDUSTRY | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | recruiting | Phase 1 | 30 | University of PennsylvaniaOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT04999761 | AB122 Platform Study | recruiting | Phase 1 | 917 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT05285358 | Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases | recruiting | Phase 1 | 12 | City of Hope Medical CenterOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT06562192 | Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | recruiting | Phase 1 | 162 | Novartis PharmaceuticalsINDUSTRY | 10 | Jul 29, 2026 | clinicaltrials |
| NCT07479485 | MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) | recruiting | Phase 1 / Phase 2 | 160 | Lepu Biopharma Co., Ltd.INDUSTRY | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07701486 | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer(VIRAGE2) | recruiting | Phase 1 / Phase 2 | 6 | Theriva Biologics SLINDUSTRY | 1 | Jul 27, 2026 | clinicaltrials |
| NCT04615013 | NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07589205 | Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors | recruiting | Phase 1 | 493 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05208762 | A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | recruiting | Phase 1 | 714 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT06131840 | A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 914 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT06834126 | Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial | recruiting | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07318805 | A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 260 | PfizerINDUSTRY | 1 | Jul 22, 2026 | clinicaltrials |
| NCT05092373 | Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax | recruiting | Phase 1 | 43 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06207305 | A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma | recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07189195 | TR-002 for the Treatment of Advanced Unresectable Metastatic Solid Tumors Unresectable or Metastatic, Refractory Pancreatic Adenocarcinoma | recruiting | Phase 1 | 52 | University of California, DavisOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT06478719 | To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization | recruiting | Phase 1 / Phase 2 | 120 | Febico Biomedical Corp.INDUSTRY | 1 | Jul 15, 2026 | clinicaltrials |
| NCT05000294 | Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types | recruiting | Phase 1 / Phase 2 | 29 | University of FloridaOTHER | 1 | Jul 13, 2026 | clinicaltrials |
| NCT04389632 | A Study of Sigvotatug Vedotin in Advanced Solid Tumors | recruiting | Phase 1 | 1,006 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 7 | Jul 6, 2026 | clinicaltrials |
| NCT04634357 | ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma(ARYA-2) | recruiting | Phase 1 / Phase 2 | 12 | Eureka Therapeutics Inc.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials